Target Trial Emulation: Glucagon-Like Peptide 1 Receptor Agonist, Sodium-Glucose Cotransporter-2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors for Kidney Outcome Prevention

GLP1RA and SGLT2i as add-on diabetes treatment was associated with lower composite and individual outcomes of kidney event and death. The association was similar across subgroups highlighting the value in primary prevention among older populations.